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Is it time for developing countries to 
adopt neonatal pulse oximetry screening 
for critical congenital heart disease?
THE DIAGNOSTIC GAP
An undetected CCHD is a significant cause of sudden or unexpected 
early neonatal death, with over 50% of patients dying at home or 
in the hospital emergency department in a California review.(6) 
This paper reported that over 30 patients per year, with a median 
age of 2 weeks, died of a missed or delayed CHD diagnosis. The 
majority of lesions were left-sided obstructive lesions. These data 
are similar to United Kingdom (UK) data: in 1 study 15% of infants 
with a CHD, which died before 12 months, were undiagnosed prior 
to death.(7) Infants detected after post-natal discharge, who survived, 
are also more likely to present with cardiovascular collapse and 
organ dysfunction.(8)
Antenatal screening for birth defects has now become routine in 
many parts of the world with history taking, blood tests and 
antenatal ultrasound and advanced methods such as amniocentesis 
and chromosomal analysis becoming part of the prenatal assess-
ment.(9,10) However, screening foetal echocardiography is not a 
universal test and in fact, routine antenatal ultrasound is limited to 
the developed world and to tertiary centres in low and middle-
income countries.
Clinical assessment of infants in post-natal wards has been the 
routine method of screening for undiagnosed defects and to ensure 
that infants are healthy prior to discharge. Cardiovascular examina-
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INTRODUCTION
A congenital heart defect (CHD) is the most common type of 
birth defect and the leading cause of infant deaths in the devel-
oped world.(1) The birth prevalence of a CHD is 1:100 - 1:150 while 
the figure of 8:1 000 is more widely reported from population 
based studies. A critical congenital heart defect (CCHD) refers to 
a potentially life-threatening cardiac abnormality; this is reported in 
2 - 3/1 000 live births.(2)
Practitioners in developing countries have long bemoaned the fact 
that CHDs are either missed entirely, or detected at an advanced 
stage, too late for full repair.(3) The benefits of early detection of 
CHDs stretches beyond the survival of neonates and infants, and 
include improved long-term outcomes for those identified early in 
their disease.(4) This is particularly important in this era of vastly 
improved outcomes and survival for children with CHDs. It is 
thought that over 80% of babies born with a CHD will survive into 
their second decade. This estimate continues to increase in the 
developed world with current intensive care and surgical proto-
cols.(5) However, infants with CCHDs are still being missed, often 
with dire consequences.
Critical congenital heart disease is often missed with 
resultant death or severe circulatory collapse and morbidity. 
Pulse oximetry screening has now been recommended for 
use in the United States of America and adopted in other 
developed world settings as part of the compulsory newborn 
screening programme. In this review we detail the rationale 
behind neonatal pulse oximetry screening, summarise the 
recent evidence and present data on method, cost-effective-
ness and acceptance. However, differences in health systems 
in the developed world and developing countries are clearly 
refl ected in the discrepancies in management and outcome 
of congenital heart disease. We discuss the importance of 
embedding a neonatal screening programme within local 
situations and suggest a method, using the infant mortality 
rate and other neonatal indicators, to position neonatal 
pulse oximetry screening into existing newborn screening 


















tion of the newborn should include auscultation, palpation of 
peripheral pulses and femoral pulses and noting the presence of 
central cyanosis. These clinical signs are difficult to detect in the 
newborn period. A UK study reported that over half of babies with 
a CHD detected in the first 12 months of life were discharged from 
hospital with a normal routine neonatal examination and that the 6 
week examination missed one-third of affected babies.(11) Early 
post-natal discharge compounds this problem and increases the risk 
of missing a CCHD.(12) In many settings in low and middle-income 
countries, births are not attended and infants are discharged within 
hours of birth without examination from a health care practitioner.
(13)
It is thus clear that in settings where antenatal ultrasound is not 
routine, where birth attendance is suboptimal and where early 
infant discharge is recommended practice, CCHDs will go unde-
tected. Pulse oximetry screening has been suggested as a strategy 
to address the diagnostic gap.(14)
PULSE OXIMETRY AND PRE- AND POST-DUCTAL 
SATURATIONS
Pulse oximetry has been used within clinical practice for some time 
and is a widely accepted method of assessing oxygen saturation.(15) 
Essentially a sensor is placed on an extremity such as a finger, toe 
or ear. Within the sensor, light emitting diodes shine red and 
infrared light through the tissue. The blood, tissue and bone at 
the application site absorb most of the light; however, some light 
passes through the extremity. A light-sensitive detector opposite 
the light source receives it, measures the amount of red and infra-
red light received by the detector and calculates the amount 
absorbed. The amount of light received by the detector indicates 
the amount of oxygen bound to the haemoglobin in the blood. 
Oxygenated haemoglobin (oxyhaemoglobinor HbO2) absorbs 
more infrared light than red light. Deoxygenatedhaemoglobin (Hb) 
absorbs more red light than infrared light. By comparing the 
amounts of red and infrared light received, the instrument can 
calculate the saturated oxygen (SpO2) reading. Pulse oximetry has 
been adopted as an essential element in the WHO surgical check-
list and several organisations are committed to supplying each 
healthcare facility in the world with pulse oximeters.(16,17)
Critical congenital heart disease refers to a potentially life-threatening 
cardiac abnormality where either the systemic or pulmonary 
circulation is dependent on a patent ductus arteriosus (PDA) such 
as pulmonary atresia or interrupted aortic arch. Table 1 details 
other situations such as transposition of great vessels with poor 
inter-circulatory mixing due to a restrictive foramen ovale and the 
obstructed form of total anomalous pulmonary venous connections 
with severe pulmonary venous hypertension. In these situations, 
abnormally low pre- and post-ductal saturations or a differential of 
≥3% between the 2 readings should alert the clinician to the 
possibility of cardiac anomalies.
CURRENT EVIDENCE FOR NEONATAL PULSE 
OXIMETRY SCREENING
The first reports suggesting the use of pulse oximetry as a screening 
test for CCHD were published in 1995.(18) These were followed by 
single unit studies before several large cohort studies were under-
taken. Firstly, a cohort study of 39 821 newborns in a single region 
in Sweden recorded a sensitivity of 82.9% and a specificity of 98%. 
Of interest is that no infant that underwent oximetry died of duct-
dependent systemic or pulmonary circulation compared to 5 such 
deaths in regions without pulse oximetry.(19) This was followed 
by a German study of 3 364 term neonates who underwent 
pulse oximetry between 6 and 36 hours. Of the 18 neonates 
with abnormal results, 50% had critical congenital heart defects. 
Sensitivity was determined to be 82% and specificity 99.9%.(20) This 
was followed by a larger multi-centre study involving 34 units in 
Saxony and 42 240 infants born between 2006 and 2008. All 
participants with prenatal diagnoses were excluded. A variety of 
pulse oximeters were used and saturations of ≥96% taken on either 
foot were deemed normal. Measurements were taken at 24 - 72 
hours. This study established that pulse oximetry screening had 
the potential to substantially reduce the postnatal diagnostic gap 
in primary, secondary and tertiary settings.(21-23)
In the UK, a study looking at cost-effectiveness of screening deter-
mined that pulse oximetry required testing within a UK setting in 
order to more accurately determine costs based on primary data.(5) 
A large multi-centre study was thus undertaken involving 20 555 
newborn babies.(24) The study reported an incidence of major 
TABLE 1: Critical congenital heart defects
Duct-dependent pulmonary blood fl ow
Tetralogy of Fallot
Tricuspid Atresia
All forms of anatomic pulmonary atresia with or without associated 
intracardiac anomalies. 
Tricuspid Incompetence/Ebsteins (Functional pulmonary atresia)
Inter-circulatory mixing
Truncus Arteriosus
Transposition of the Great Arteries (TGA)
Total Anomalous Pulmonary Venous Drainage (TAPVD)
Systemic Hypoperfusion
Hypoplastic Left Ventricle/Critical aortic stenosis
Critical coarctation/Interrupted aortic arch
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congenital heart disease of 2.6:1 000 live births with 24 babies 
with a CCHD detected. The sensitivity reported was 75% (95% CI 
53.29 - 90.23) for critical cases, 49.06% (95% CI 35.06 - 63.16) for 
a major CHD with a specificity 99.16% (95%CI 99.02 - 99.28) and 
false positive rate of 0.8%.(24)
When reviewed within a systematic review and meta-analysis,(25) 
some key observations were described: 
 ■ Pulse oximetry detected 30 additional cases of a CCHD per 
100 000 live births. 
 ■ The false positive rate, if tested at >24 hours was 0.05 (0.02 - 
0.12), which equates to a specificity of 99.95% and sensitivity 
of 77.5 (61.8 - 88.0).
The cost-effectiveness analysis based on these data revealed a 
primary cost of £24 000 per case of timely diagnosis.(26) With a 
threshold £100 000, the probability of pulse oximetry being cost 
effective is greater than 90%. This is plausible if a newborn gained 
only 5 Quality Adjusted Life Years (QALYs).(27)
This assessment also reviewed acceptability of the intervention and 
was able to demonstrate that pulse oximetry screening was widely 
acceptable to parents. Careful communication of results needed to 
be conducted, both to minimise parental anxiety and to avoid 
false reassurance.(28) Parents may need information on heart defects 
in order to better understand both the screened conditions and 
the importance of testing. Participants from all groups felt that the 
test should be a routine part of standard care and felt pleased to 
have had the opportunity to take the test.(28) Of importance was 
the additional finding in those with false positive results. In 49/169 
families with false positive results, pulse oximetry detected major 
congenital heart lesions or other critical conditions (infective, 
respiratory) which required intervention.(28)
Additional studies have now been performed in the US,(29-32) UK 
and Europe(33-35) while several studies have been performed out-
side of these large and well-resourced centres.(36) In Poland a 
prospective screening pulse oximetry test was conducted in 51 
neonatal units in the Mazovia province between 2006 and 2008, 
screening over 52 993 newborns with a sensitivity of 78.9% and a 
specificity of 99.9%.(37) This protocol isolated asymptomatic from 
symptomatic infants. Only asymptomatic term newborns were 
screened and included in the analysis. In this asymptomatic group, 
pulse oximetry was performed between the second and 24th 
hour of life with test performed at a median fifth hour of life. 
Defects detected included transposition of the great arteries and 
hypoplastic left heart syndrome and increased the perinatal 
detection of CCHD from 76.8% to 95%.
In contrast, an earlier study from India(38) attempted to introduce 
pulse oximetry screening in a less resourced setting. Of interest was 
the use of different cadres of healthcare practitioners: the on-site 
paediatrician performed clinical evaluation while pulse oximetry 
was performed by a study nurse. Bedside echocardiography was 
performed by a research officer while only those babies with 
abnormal echoes were reviewed by a paediatric cardiologist. In this 
context the sensitivity of pulse oximetry with clinical examination 
was low with a sensitivity of <20%. This study expounded upon 
the limitations of technical and human factors as well as limited 
echo capacity. Only major lesions had a confirmatory echocar-
diogram immediately, minor lesions were echoed by 6 weeks. 
PULSE OXIMETRY PROTOCOLS: HOW, WHERE 
AND WHEN? 
How should pulse oximetry be performed?
It is critical to use a pulse oximeter licensed for use in neonates 
and infants and shown to produce stable, accurate recordings free 
from motion artefacts. It is important to standardise instruments, 
train staff in recognising normal plethysmogrpahic waveforms and 
to recognise pitfalls in measurements such as poor perfusion, 
severe haemolytic jaundice or tachyarrhythmias.(39)
Where should the probe be positioned? 
Probe positioning is crucial as inaccurately low readings might occur 
when the probe is inappropriately placed on the small fingers of 
neonates and infants.(40) This pitfall can be avoided by using probes 
of appropriate size for neonates and infants. The threshold for an 
abnormal saturation is important in considering the sensitivity and 
specificity of the test; the higher the percentage saturation thresh-
olds the greater the sensitivity but the lower the specificity, and 
the converse is true for a lower cut-off. The most frequently used 
upper threshold in the published studies is 95%.(41) Some have used 
post-ductal saturations as a single measurement,(42) while others 
used both pre- and post-ductal saturations and included a differ-
ence between the two in the definition of abnormality.(25) Use of 
a differential criterion may increase the likelihood of detecting 
those with obstructive left heart lesions, such as Coarctation of 
the Aorta, where the ductus supplies some of the systemic circula-
tion and may result in a difference in saturation between the upper 
and lower limbs.
When should the reading be taken?
The increasing trend towards earlier discharge in North America, 
Scandinavia and the UK is well established and is likely to continue. 
This will result in an increasing number of babies being discharged 
from hospital before a CCHD is manifested.(12) This has influenced 
the outcomes of studies utilising different time periods for 
screening - in general those that screened between 24 - 72 hours 
had the lowest false positive rates(25) yet risked potential collapse 
within 12 - 24 hours in left sided obstructive lesions. It is thus 
important to take into consideration the policy of the unit and 
screen each infant prior to discharge regardless of the age – those 


















failing an early pulse oximetry screening test with a normal clinical 
evaluation could have a repeat pulse oximetry test performed at 
about 24 hours (Figure 1).
ADVOCACY, POLICY AND LAW
In 2012, following a series of pulse oximetry screening studies, the 
American Academy of Paediatrics (AAP) released a policy state-
ment endorsing the recommendation of pulse oximetry screening 
for critical congenital heart disease.(42) This initiated the process of 
legislating for pulse oximetry in many states in the United States of 
America (USA). This recommendation has not been replicated in 
other countries and mixed feelings still exist regarding the routine 
use of pulse oximetry screening.(43,44)
The debate has, however, succeeded in raising awareness of con-
genital heart disease and the importance of early detection and the 
policy of neonatal screening programmes. In order to introduce and 
run an effective newborn screening programme, some critical 
elements need to be addressed namely:
 ■ An innovative and sustainable financial strategy. 
 ■ Strong leadership in developing and working towards national 
programme implementation.
 ■ Strategic advocacy programmes to ensure programme sus-
tainability.
 ■ Strong multi-sectoral collaboration in planning and implemen-
tation.
 ■ A comprehensive public health system.
Introducing a newborn screening programme has clear benefits, yet 
implementation has been less than ideal. A survey undertaken in 
the South African private health care sector of hearing screening 
showed that newborn hearing screening was only available in 53% 
of private units in which only 14% provided universal screening.(45) 
Neonatal screening for congenital hypothyroidism however has 
been well established with coverage of over 75% reported in less 
resourced nations.(46,47) A strongly committed team, together with 
governmental support, financial costs related to cover and treat-
ment and adequate teaching and training are essential in establish-
ing comprehensive newborn screening programmes.(48) All of these 
elements are crucial in developing a pulse oximetry screening pro-
gramme, even if underpinned by the recent evidence of sensitive, 
specific and cost-effective protocols in studies.
FIGURE 1:  Pulse oximetry protocol
















































SaO2 <95% in either Rt foot or 
Rt hand or ≥3% difference
CHD absent or present Repeat after one hour







Repeat after an hour or 
delay discharge until 
24 hours
Pulse oximetry at 




After the endorsement by the AAP, efforts were co-ordinated by 
several advocacy groups to introduce pulse oximetry as law. As a 
result, several states in the USA have adopted laws requiring 
newborn screening for CCHD as depicted on the CCHD screening 
map in Figure 2. It is unprecedented for a health intervention to 
be adopted as law in the United States at this scale and within such 
a relatively short period of time, with the major lobbyists being 
parent and advocacy groups rather than medical professionals.
IS THIS REALLY AN OPTION FOR DEVELOPING 
COUNTRIES?
The healthcare systems in the developing world are vastly different 
from those in the industrialised nations. Within large developing 
countries, significant differences exist in health care indices such as 
infant mortality rate (IMR) and priorities for health care. In India 
the national IMR value is 44;48 for rural India and 29 for urban 
areas.(50) There is a very wide gap in IMR between states with good 
human development indices (Kerala IMR 12) and those with less 
well developed health care systems (Odisa IMR 57). This gap is also 
present in emerging economies such as South Africa, China and 
Brazil. The causes of childhood mortality is remarkably different 
in areas with low IMR vis-à-vis those with high IMR. Typically, in the 
high IMR areas, most of the infant and childhood deaths are 
attributed to preventable causes like malnutrition, diarrheal illness, 
pneumonia and birth asphyxia.(51) However, once the IMR values 
start declining, the proportion of childhood deaths due to congenital 
malformations like CCHD becomes more important. 
The overall data about the utility of pulse oximetry in the developed 
world seems to favour its introduction as a screening tool for neo-
natal CCHD screening. Following these studies and the active 
campaigning by advocacy groups, several countries have introduced 
mandatory pulse oximetry screening as a part of routine newborn 
screening. However, the major public health concerns about 
mandatory screening centres around the issue of false positives.(52) 
Assuming sensitivity and specificity values based on data from the 
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FIGURE 2:  Newborn screening for CCHD.  With kind permission from the Newborn Foundation Coalition.(49)
Legislation introduced Legislation enacted Regulatory addition to NBS panel Multi-centre screening or pilot project


















developed world and applying the Bayes Theorem, the post-test 
probability of CCHD following a positive pulse oximetry screen 
would be 16%. If we take the data from the developing world and 
re-apply the Bayes theorem, this probability would further decrease 
to 3%. Considering the fact that the overall accuracy of pulse 
oximetry in mass community settings is much lower than in trial 
settings, the overall prevalence of false alarms is likely to be much 
higher in community based screening programmes. Consequently, 
if we routinely practice pulse oximetry screening for all asympto-
matic newborns in a community, the absolute number of referrals 
for further testing (principally paediatric echocardiography) is going 
to be very high. This may simply overwhelm the already delicate 
health care facilities in developing countries. To add to the problem, 
many developing countries do not have clear health policies or 
infrastructure to treat children with a CCHD, especially in public 
sector, government funded hospitals. 
Hence, introduction of newer neonatal screening tests should 
complement the local child health care priorities and should be 
dictated principally by the local needs rather than based on data 
from a completely different healthcare system. Ideally, this should 
be based on local prevalence data, currently available infrastructure 
for treatment once a diagnosis is made and local health economics 
and priorities. Essentially, as Winston Churchill famously said, “It is 
not enough that we do our best, sometimes we have to do what 
is required”. The following discussion will examine the role of 
pulse oximetry in the context of developing economies with this 
background in mind. 
PULSE OXIMETRY IN AREAS WITH LOW IMR
A typical situation where this scenario exists within India is the 
state of Kerala from where a prospective study on clinical utility of 
pulse oximetry for newborn CCHD screening was published.(38) 
The current IMR in Kerala is 12 and this is a very clear reflection of 
reduction in mortality due to preventable causes. The Millennium 
development goal (MDG) target for IMR in Kerala by 2015 is 5.5. It 
is very clear that in order to achieve this we need to focus on other 
causes of childhood mortality of which major congenital malfor-
mations, especially CCHDs, contribute significantly. The feasibility 
of performing neonatal heart surgeries with in-hospital mortality 
almost comparable to developed nations has been already reported 
from Kerala.(53) Hence, the focus has to shift towards early detec-
tion of critical CHD, more efficient transport of neonates with a 
CCHD to a tertiary centre before clinical deterioration and reducing 
the pre-operative morbidity. Hence, routine screening of all new-
borns with pulse oximetry seems to be an attractive concept in 
these health care systems. In addition, pulse oximetry screening 
may facilitate early diagnosis and management of severe non-
cardiac problems like respiratory illnesses, thereby contributing 
further to reduction in neonatal mortality. In tandem with pulse 
oximetry screening, the following additional measures may also 
facilitate early detection and safe transport of infants with a CCHD. 
 ■ Improving the efficiency of antenatal screening for serious 
CHDs in early mid trimester scans by educating obstetric sono-
graphers on foetal heart screening protocols. 
 ■ In-utero transport of foetuses with critical but repairable CHDs 
like TGA and Coarctation for planned delivery in a tertiary 
cardiac care facility. 
 ■ Training of healthcare personnel in primary health centres and 
district level hospitals to facilitate more efficient neonatal car-
diac evaluation, including pulse oximetry. The importance of 
repeat testing in case of an initial abnormal screen needs to be 
highlighted. 
 ■ Training of neonatologists in bedside echocardiography as a 
screening tool for major CHDs in the event of a positive pulse 
oximetry screen. This can avoid a lot of referrals due to false 
positive screens, thus saving time and costs and reducing the 
risk associated with transport. 
 ■ Improving networking and transfer of data between peripheral 
centres and tertiary hospitals through newer strategies like 
Telemedicine. 
 ■ Improving facilities for the transport of sick neonates to a 
tertiary centre using monitored systems of transport.
The situation in urban South Africa is remarkably similar to that in 
India with low infant mortality rates within cities with largely 
privately insured patients and excellent cardiac surgical centres. 
Based on evidence presented in 2010,(54) it is clear that there is a 
significant diagnostic gap with far less patients being diagnosed 
with critical congenital heart disease than expected, even in private 
units. It is thus an appropriate consideration to investigate the 
feasibility of launching pulse oximetry programmes within pilot 
South African sites.
PULSE OXIMETRY IN AREAS WITH HIGH IMR
These are areas where the basic child health care systems need to 
be energised and deaths, due to preventable causes, prevented. 
Management of critical and complex CHDs may not be a very 
major public level child health priority in these areas at present. 
In these areas, the current focus should be on raising awareness 
about CHDs, especially those with good outcomes, amongst the 
health care professionals and ensuring that the available resources 
are channelled more efficiently towards treatment of such lesions. 
Pulse oximetry may aid early detection of correctable non-cardiac 
problems like respiratory illnesses. We need to ensure that the 
healthcare providers who practice pulse oximetry are adequately 
trained in the technique(14) which will have an impact on the entire 
health system. We need more data from these contexts about 
the utility of newborn screening using newer techniques, like pulse 
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oximetry, before recommending this strategy as standard of care 
for a community level practice. Furthermore, we need more data 
about the cost effectiveness of newer screening strategies to 
ensure that the cost of case finding is in tandem with the infra-
structure available to ensure effective follow-up action and aftercare 
including tertiary cardiac care. This requires an integration of 
medical personnel, research bodies, local academic organisations 
and the government agencies keeping the needs of the average 
citizen of the community in the centre of the algorithm. Areas of 
South Africa that are severely under-resourced, such as the 
provinces without any paediatric cardiac services,(55) will need signi-
ficant infrastructure and health system development prior to the 
implementation of a new screening programme.
CONCLUSION
Pulse oximetry is a safe, feasible, easy test which is also cost-
effective. It has been shown to be acceptable to parents and 
medical staff alike and is unprecedented as a screening test to 
detect CCHD. However, implementation necessitates integra-
tion into existing newborn screening programmes with commit-
ment to training, sustainability and strengthening of collaborating 
healthcare infrastructure. The optimal programme for early detec-
tion, follow-up and data management in existing programmes must 
be developed while CCHD screening must be integrated with 
current birthing services, ideally with centralised data management 
and quality control. Contextualising the local situation is key, as is 
consideration of primary mortality indicators. Until infants born in 
developing countries have access to comprehensive primary health-
care services (including antenatal assessment, qualified birth 
attendance and post-natal examination) and only if cardiac services 
have improved concurrently in many of the regions under discus-
sion, pulse oximetry screening will not change the undeniable fact 
that infants with critical congenital heart disease will continue to be 
missed and die, many undiagnosed.
"No mother should find out about her child's heart defect from the 
coroner" - Kristine Brite McCormick, Indiana.(56)
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